Peripheral blood DNA methylation levels in the NCAPH2/LMF2 promoter region were significantly decreased in patients with AD and those with amnestic mild cognitive impairment (aMCI) (Kobayashi et al., 2016); therefore, these are considered to be a potentially useful biomarker for the diagnosis of AD. Here, LMF2 is linked to Alzheimer disease.